Kohjin Bio Co., Ltd. (TYO:177A)
Japan · Delayed Price · Currency is JPY 1,219.00
+28.00 (2.35%)
Mar 6, 2026, 3:02 PM JST
Kohjin Bio Revenue
Kohjin Bio had revenue of 1.29B JPY in the quarter ending December 31, 2025, a decrease of -9.11%. This brings the company's revenue in the last twelve months to 5.07B, down -1.46% year-over-year. In the fiscal year ending March 31, 2025, Kohjin Bio had annual revenue of 5.21B with 9.14% growth.
Revenue (ttm)
5.07B
Revenue Growth
-1.46%
P/S Ratio
1.23
Revenue / Employee
30.38M
Employees
167
Market Cap
6.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.21B | 436.00M | 9.14% |
| Mar 31, 2024 | 4.77B | 28.00M | 0.59% |
| Mar 31, 2023 | 4.74B | 795.00M | 20.14% |
| Mar 31, 2022 | 3.95B | 809.83M | 25.81% |
| Mar 31, 2021 | 3.14B | 861.62M | 37.86% |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.89B |
| Linical | 9.32B |
| Soiken Holdings | 4.58B |
| CellSource | 3.71B |
| OncoTherapy Science | 784.00M |
| PRISM BioLab Co.,LTD | 684.61M |
| Chiome Bioscience | 593.29M |
| Carna Biosciences | 579.06M |